What other biotechs are you guys looking at these days?
March 8, 2012
09:14 EDT CLDX theflyonthewall.com: Celldex shares should be bought into study results, says Roth Capital Roth Capital recommends that investors buy Celldex's stock ahead of ASCO in June, as the firm expects the stock to climb as the Street anticipates that the results of a Phase IIb study of the company's CDX-011 in metastatic breast cancer will be presented at that conference. The firm raised its target on Celldex to $9 from $6 and reiterates a Buy rating. :theflyonthewall.com
GATTEX (teduglutide) for treatment of SBS should be approved this year (despite the cancer scare that arose and cut price almost in half). They have also published good results from their P3 trail for NPS558 for hypoparathyroidism.
Rumor is that Takeda may be interested in NPS once GATTEX approved, as they bought NYCOMED on their european approval of teduglutide. Even at its current price, there's still good upside without buyout.
Your pick of Celldex was, and is, wise. You posted six months ago, and at that time CLDX was at $3.98 for a short time in late April but has been in a steady climb all year. This week Celldex broke into $6.00 convincingly. Lots of Catalyst through the end of this year, and according to the CEO, Celldex is speaking with several partner suitors. I Think we will see many more upgrades this year as the excitement surrounding CDX-011 continues to build.